

Zinplava[™] (bezlotoxumab) – Expanded indication

- On May 26, 2023, the <u>FDA approved</u> Merck's <u>Zinplava (bezlotoxumab)</u>, to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence.
 - Zinplava was previously approved for this indication in adults only.
 - Zinplava is not indicated for the treatment of CDI. Zinplava is not an antibacterial drug.
 Zinplava should only be used in conjunction with antibacterial drug treatment of CDI.
- The use of Zinplava in pediatric patients 1 year of age and older is supported by evidence from adequate and well-controlled trials in adults with additional pharmacokinetic and safety data in pediatric patients aged 1 year and older. The adverse reactions and the pharmacokinetics observed in pediatric patients were comparable to that observed in adult patients.
- The most common adverse reactions (> 10%) with Zinplava use in pediatric patients were pyrexia and headache
- The recommended dose of Zinplava is a single dose of 10 mg/kg administered as an intravenous infusion over 60 minutes. The safety and efficacy of repeat administration of Zinplava in patients with CDI have not been studied.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.